138 related articles for article (PubMed ID: 279298)
1. Enhancement of chemotherapeutic effect by entrapping 1-beta-D-arabinofuranosylcytosine in lipid vesicles and its mode of action.
Kataoka T; Kobayashi T
Ann N Y Acad Sci; 1978; 308():387-94. PubMed ID: 279298
[TBL] [Abstract][Full Text] [Related]
2. Effect and mode of action of N4-behenoyl-beta-D-arabinofuranosylcytosine.
Kataoka T; Sakurai Y
Recent Results Cancer Res; 1980; 70():147-51. PubMed ID: 7355245
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of anti-tumor activity of 1-beta-D-arabinofuranosylcytosine by encapsulation in liposomes.
Kobayashi T; Kataoka T; Tsukagoshi S; Sakurai Y
Int J Cancer; 1977 Oct; 20(4):581-7. PubMed ID: 914397
[TBL] [Abstract][Full Text] [Related]
4. Use of liposomes for the enhancement of the cytotoxic effects of cytosine arabinoside.
Mayhew E; Papahadjopoulos D; Rustum YM; Dave C
Ann N Y Acad Sci; 1978; 308():371-86. PubMed ID: 279297
[No Abstract] [Full Text] [Related]
5. Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo.
Ganapathi R; Krishan A; Wodinsky I; Zubrod CG; Lesko LJ
Cancer Res; 1980 Mar; 40(3):630-3. PubMed ID: 7471083
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles.
Mayhew E; Papahadjopoulos D; Rustum YM; Dave C
Cancer Res; 1976 Dec; 36(12):4406-11. PubMed ID: 187321
[TBL] [Abstract][Full Text] [Related]
7. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
Rubas W; Supersaxo A; Weder HG; Hartmann HR; Hengartner H; Schott H; Schwendener R
Int J Cancer; 1986 Jan; 37(1):149-54. PubMed ID: 3941019
[TBL] [Abstract][Full Text] [Related]
8. Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine.
Hong F; Mayhew E
Cancer Res; 1989 Sep; 49(18):5097-102. PubMed ID: 2766280
[TBL] [Abstract][Full Text] [Related]
9. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
Riva CM; Rustum YM; Preisler HD
Semin Oncol; 1985 Jun; 12(2 Suppl 3):1-8. PubMed ID: 3859925
[No Abstract] [Full Text] [Related]
11. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia.
Rustum YM; Dave C; Mayhew E; Papahadjopoulos D
Cancer Res; 1979 Apr; 39(4):1390-5. PubMed ID: 421223
[No Abstract] [Full Text] [Related]
12. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
Allen TM; Mehra T; Hansen C; Chin YC
Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
[TBL] [Abstract][Full Text] [Related]
13. Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues.
Ellens H; Rustum Y; Mayhew E; Ledesma E
J Pharmacol Exp Ther; 1982 Aug; 222(2):324-30. PubMed ID: 7097552
[TBL] [Abstract][Full Text] [Related]
14. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
Oh-ishi J; Kataoka T; Tsukagoshi S; Sakurai Y; Shibukawa M; Kobayashi H
Cancer Res; 1981 Jun; 41(6):2501-6. PubMed ID: 7237444
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine.
Cass CE; Muzik H; Paterson AR
Cancer Res; 1975 May; 35(5):1187-93. PubMed ID: 1120308
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells.
Roberts D; Peck C; Hilliard S; Wingo W
Cancer Res; 1979 Oct; 39(10):4048-54. PubMed ID: 476642
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
[TBL] [Abstract][Full Text] [Related]
19. Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-beta-D-arabinofuranosyl cytosine.
Schwendener RA; Schott H
Int J Cancer; 1992 May; 51(3):466-9. PubMed ID: 1592536
[TBL] [Abstract][Full Text] [Related]
20. Inability of liposome encapsulated 1-beta-D-arabinofuranosylcytosine nucleotides to overcome drug resistance in L1210 cells.
Rustum YM; Mayhew E; Szoka F; Campbell J
Eur J Cancer Clin Oncol; 1981 Jul; 17(7):809-17. PubMed ID: 7199474
[No Abstract] [Full Text] [Related]
[Next] [New Search]